Structure–activity insights into Benzimidazole-based Ir(III) cyclometallated complexes for cancer therapy

Mónica Martínez-Estévez; María Tejera-Ruiz; M. Concepción Gimeno

doi:10.1039/d5dt02366a

January 1, 2025Dalton TransactionsOpen Access

Structure–activity insights into Benzimidazole-based Ir(III) cyclometallated complexes for cancer therapy

View Full Paper

Ask AI

Bookmark

Share

Key Points

Benzimidazole-based Ir(III) complexes improve cancer therapy outcomes with unique structural features.
Key insights focus on specific functionalities of ligands, enhancing therapeutic efficacy against cancer.
Observational analysis of various cyclometallated complexes provides insights on their anti-cancer activity.
Findings support the potential of these complexes in developing novel cancer treatments.

Implication

Analysis reveals Benzimidazole-based Ir(III) complexes enhance cancer therapy, suggesting new treatment options.

Abstract

A family of cyclometallated Ir(III) complexes incorporating benzimidazole-based C^N ligands and ancillary diimines with distinct functionalities, 2-(pyridin-2-yl)-1H-benzo[d]imidazole (L1), 4-(1H-benzo[d]imidazol-2-yl)thiazole (L2), di(pyridin-2-yl)amine (L3), [2,2′-bipyridine]-4,4′-dicarboxylic acid (L4), and dibutyl [2,2′-bipyridine]-4,4′-dicarboxylate (L5), has...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Martínez-Estévez et al. (2025) studied this question.

synapsesocial.com/papers/69337cfbb3f947a0a125a5ef https://doi.org/10.1039/d5dt02366a

View Full Paper

Ask AI

Bookmark

Share

Structure–activity insights into Benzimidazole-based Ir(III) cyclometallated complexes for cancer therapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Structure–activity insights into Benzimidazole-based Ir(III) cyclometallated complexes for cancer therapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading